{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:36:59Z","timestamp":1793558219658,"version":"4.5.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:sec id=\"ab-crv240013-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Integration of molecular biomarker information into systemic therapy has become standard practice in breast cancer care. However, its implementation in guiding radiotherapy (RT) is slower. Although postoperative RT is recommended for most patients after breast-conserving surgery and, depending on risk factors, following mastectomy, emerging evidence has indicated that patients with low scores on gene expression signatures or selected clinical-pathological features may have very low local recurrence rates. This narrative review explored the potential of biomarker-directed personalized RT approaches, which may optimize treatment strategies and be associated with improved patient outcomes and experiences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv240013-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Distinctions between prognostic and predictive biomarkers were highlighted, emphasizing the importance of analytical and clinical validity in biomarker-based studies. Findings from studies investigating the prognostic and predictive value of various genomic signatures and immunohistochemical markers for guiding breast RT were presented. These included the Adjuvant Radiotherapy Intensification Classifier and the Profile for the Omission of Local Adjuvant Radiation, which have shown potential in predicting RT benefits. The genomic-adjusted radiation dose and role of tumor-infiltrating lymphocytes were also discussed. Ongoing clinical trials exploring the use of biomarkers in ductal carcinoma in situ and invasive breast cancer to refine RT decision-making were illustrated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv240013-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this narrative review suggest that evidence-based shared decision-making is crucial to optimize treatment according to the individual\u2019s predicted benefits and risks along with their personal preferences. Incorporation of biomarker-directed approaches in RT for breast cancer may hold promise for personalized treatment, potentially facilitating omission of RT for patients at low risk of recurrence, while identifying those who may benefit from intensified therapy. This personalized RT approach may be associated with improved clinical outcomes and quality of life and facilitate decision-making for people with breast cancer. However, there remains a need for robust clinical and analytical validation of biomarkers to ensure reliability and clinical utility for RT optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5780","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:00:58Z","timestamp":1737025258000},"page":"329","source":"Crossref","is-referenced-by-count":27,"title":["Biomarker-Directed Radiotherapy in Breast Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Icro","family":"Meattini","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences M. Serio, University of Florence, Florence, Italy"},{"name":"Radiation Oncology and Breast Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Coles","sequence":"additional","affiliation":[{"name":"Breast Cancer Clinical Oncology, Department of Oncology, University of Cambridge, Cambridge, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Tramm","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Borghesi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Arezzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krug","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Montero","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, HM Hospitales, Madrid, Spain"},{"name":"Facultad de Ciencias de la Salud, Universidad Camilo Jos\u00e9 Cela, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Nardone","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Salvestrini","sequence":"additional","affiliation":[{"name":"Radiation Oncology and Breast Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Valzano","sequence":"additional","affiliation":[{"name":"Radiation Oncology and Breast Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Valentini","sequence":"additional","affiliation":[{"name":"Centro Eccellenza Oncologia e Diagnostica per Immagini, Ospedale Isola Tiberina\u2013Gemelli Isola, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[{"name":"Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy"},{"name":"Perugia General Hospital, Sant\u2019Andrea delle Fratte, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium"},{"name":"University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Assisi Think Tank Meeting Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Arenas","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth J.","family":"Boersma","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Bolukbasi","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Ciabattoni","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Franco","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Genovesi","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Kaidar Person","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Kouloulias","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Krengli","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Leonardi","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lozza","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marazzi","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Masiello","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio G.","family":"Morganti","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Offersen","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Palumbo","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pedretti","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Perrucci","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Ratosa","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rivera","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lurdes","family":"Garcia Trigo","sequence":"additional","affiliation":[{"name":"for the Assisi Think Tank Meeting Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"crv240013r1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer.","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"crv240013r2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/biomedicines11010098","article-title":"The prognostic and predictive value of genomic assays in guiding adjuvant breast radiation therapy.","volume":"11","author":"Beyer","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"crv240013r3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.23.02270","article-title":"Omission of radiotherapy after breast-conserving surgery for women with breast cancer with low clinical and genomic risk: 5-year outcomes of IDEA.","volume":"42","author":"Jagsi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"crv240013r4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer.","volume":"388","author":"Kunkler","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"crv240013r5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa2302344","article-title":"Omitting radiotherapy after breast-conserving surgery in luminal a breast cancer.","volume":"389","author":"Whelan","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"crv240013r6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-016-3998-2","article-title":"The 2016 Assisi Think Tank Meeting on breast cancer: white paper.","volume":"160","author":"Aristei","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"crv240013r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102967","article-title":"The 2018 Assisi think tank meeting on breast cancer: International expert panel white paper.","volume":"151","author":"Arenas","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"crv240013r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103774","article-title":"Ways to improve breast cancer patients\u2019 management and clinical outcome: the 2020 Assisi Think Tank Meeting.","volume":"177","author":"Aristei","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"crv240013r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104035","article-title":"The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer.","volume":"187","author":"Aristei","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"crv240013r11","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1093\/bioinformatics\/bty357","article-title":"Distinguishing prognostic and predictive biomarkers: an information theoretic approach.","volume":"34","author":"Sechidis","year":"2018","journal-title":"Bioinformatics"},{"issue":"9793","key":"crv240013r12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"crv240013r13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics.","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"issue":"7","key":"crv240013r14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group.","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"crv240013r15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"crv240013r16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/bjc.2015.222","article-title":"Clinical utility of the IHC4+C score in estrogen receptor-positive early breast cancer: a prospective decision impact study.","volume":"113","author":"Yeo","year":"2015","journal-title":"Br J Cancer"},{"key":"crv240013r17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1471-2407-14-177","article-title":"Analytical validation of the PAM50-based Prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens.","volume":"14","author":"Nielsen","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"crv240013r18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1373\/clinchem.2006.076497","article-title":"Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.","volume":"53","author":"Cronin","year":"2007","journal-title":"Clin Chem"},{"issue":"13","key":"crv240013r19","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.3390\/cancers15133504","article-title":"Validation of in vitro trained transcriptomic radiosensitivity signatures in clinical cohorts.","volume":"15","author":"O\u2019Connor","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"18","key":"crv240013r20","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1158\/1078-0432.CCR-12-0891","article-title":"Validation of a radiosensitivity molecular signature in breast cancer.","volume":"18","author":"Eschrich","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"crv240013r21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/ijc.33730","article-title":"Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmastectomy radiotherapy? an analysis based on RecurIndex assay.","volume":"149","author":"Zhang","year":"2021","journal-title":"Int J Cancer"},{"issue":"35","key":"crv240013r22","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.19.00761","article-title":"Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer.","volume":"37","author":"Sj\u00f6str\u00f6m","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"crv240013r23","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1200\/JCO.22.00655","article-title":"Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer.","volume":"41","author":"Sj\u00f6str\u00f6m","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"crv240013r24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1056\/NEJMoa040595","article-title":"Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.","volume":"351","author":"Fyles","year":"2004","journal-title":"N Engl J Med"},{"key":"crv240013r25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radonc.2019.04.034","article-title":"REQUITE: a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.","volume":"138","author":"Seibold","year":"2019","journal-title":"Radiother Oncol"},{"issue":"2","key":"crv240013r26","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/1078-0432.CCR-18-0777","article-title":"Association of CD4+ radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with &gt;10-year follow-up.","volume":"25","author":"Veldwijk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"crv240013r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctro.2019.06.001","article-title":"Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity.","volume":"18","author":"Talbot","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"issue":"23","key":"crv240013r28","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.3390\/cancers13236103","article-title":"Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS).","volume":"13","author":"W\u00e4rnberg","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"crv240013r29","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy.","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"23","key":"crv240013r30","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk.","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"crv240013r31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1069059","article-title":"Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ.","volume":"13","author":"Dabbs","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"crv240013r32","doi-asserted-by":"publisher","first-page":"e1055","DOI":"10.1200\/OP.20.00992","article-title":"Cost-effectiveness analysis of no adjuvant therapy versus partial breast irradiation alone versus combined treatment for treatment of low-risk DCIS: a microsimulation.","volume":"17","author":"Ward","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"crv240013r33","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","article-title":"The clinical utility of DCISionRT on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery.","volume":"28","author":"Shah","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"crv240013r34","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/j.clbc.2020.10.007","article-title":"Cost-effectiveness analysis of biological signature DCISionRT use for DCIS treatment.","volume":"21","author":"Kim","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"crv240013r35","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa004","article-title":"Cost effectiveness of DCISionRT for guiding treatment of ductal carcinoma in situ.","volume":"4","author":"Raldow","year":"2020","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"3","key":"crv240013r36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.radonc.2016.06.017","article-title":"Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.","volume":"121","author":"Andreassen","year":"2016","journal-title":"Radiother Oncol"},{"issue":"2","key":"crv240013r37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jclinpath-2015-203212","article-title":"Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.","volume":"69","author":"Dodson","year":"2016","journal-title":"J Clin Pathol"},{"issue":"9804","key":"crv240013r38","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"crv240013r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108058","article-title":"Omission of radiation therapy after breast conserving surgery for older women at low-risk of local recurrence: one option among many.","volume":"50","author":"Meattini","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"crv240013r40","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"crv240013r41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology.","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"crv240013r42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline.","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"crv240013r43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial.","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"crv240013r44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage Breast Cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"crv240013r45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.22.02690","article-title":"Locoregional breast cancer recurrence in the European Organisation for Research and Treatment of Cancer 10041\/BIG 03-04 MINDACT Trial: analysis of risk factors including the 70-gene signature.","volume":"42","author":"Alaeikhanehshir","year":"2024","journal-title":"J Clin Oncol"},{"issue":"28","key":"crv240013r46","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1200\/JCO.2017.72.7263","article-title":"Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the Swedish Breast Cancer Group 91 radiotherapy randomized clinical trial.","volume":"35","author":"Sj\u00f6str\u00f6m","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv240013r47","doi-asserted-by":"publisher","first-page":"R62","DOI":"10.1186\/bcr1614","article-title":"Predicting a local recurrence after breast-conserving therapy by gene expression profiling.","volume":"8","author":"Nuyten","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"5","key":"crv240013r48","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr1771","article-title":"Gene expression profiling and histopathological characterization of triple-negative\/basal-like breast carcinomas.","volume":"9","author":"Kreike","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"28","key":"crv240013r49","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2005.02.5676","article-title":"Genomic prediction of locoregional recurrence after mastectomy in breast cancer.","volume":"24","author":"Cheng","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv240013r50","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/bcr1997","article-title":"Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy.","volume":"10","author":"Nim\u00e9us-Malmstr\u00f6m","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"12","key":"crv240013r51","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1158\/1078-0432.CCR-08-2644","article-title":"Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.","volume":"15","author":"Kreike","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"crv240013r52","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2009.23.7610","article-title":"Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.","volume":"28","author":"Mamounas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"crv240013r53","first-page":"199","article-title":"Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer.","volume":"8","author":"Sabatier","year":"2011","journal-title":"Cancer Genomics Proteomics"},{"issue":"6","key":"crv240013r54","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/1078-0432.CCR-11-1954","article-title":"Search for a gene expression signature of breast cancer local recurrence in young women.","volume":"18","author":"Servant","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"crv240013r55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-014-3188-z","article-title":"Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.","volume":"148","author":"Drukker","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"crv240013r56","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-14-2898","article-title":"Development and validation of a novel radiosensitivity signature in human breast cancer.","volume":"21","author":"Speers","year":"2015","journal-title":"Clin Cancer Res"},{"key":"crv240013r57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ebiom.2016.02.022","article-title":"An eighteen-gene classifier predicts locoregional recurrence in post-mastectomy breast cancer patients.","volume":"5","author":"Cheng","year":"2016","journal-title":"EBioMedicine"},{"issue":"19","key":"crv240013r58","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/1078-0432.CCR-18-0825","article-title":"Integrating radiosensitivity and immune gene signatures for predicting benefit of radiotherapy in breast cancer.","volume":"24","author":"Cui","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"crv240013r59","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/bjs\/znaa089","article-title":"PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+\/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.","volume":"108","author":"Fitzal","year":"2021","journal-title":"Br J Surg"},{"issue":"3","key":"crv240013r60","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ijrobp.2015.06.021","article-title":"Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer.","volume":"93","author":"Torres-Roca","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"crv240013r61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"key":"crv240013r62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ebiom.2019.08.019","article-title":"Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management.","volume":"47","author":"Ahmed","year":"2019","journal-title":"EBioMedicine"},{"issue":"9","key":"crv240013r63","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"issue":"20","key":"crv240013r64","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-14-0458","article-title":"Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort.","volume":"20","author":"Tramm","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"14","key":"crv240013r65","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.18.02157","article-title":"Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial.","volume":"37","author":"Kov\u00e1cs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv240013r66","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/0284186X.2021.1989629","article-title":"Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort.","volume":"61","author":"Tramm","year":"2022","journal-title":"Acta Oncol"},{"issue":"14","key":"crv240013r67","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1002\/cam4.4050","article-title":"Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.","volume":"10","author":"Mouabbi","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"crv240013r68","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ.","volume":"109","author":"Rakovitch","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"crv240013r69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-018-4693-2","article-title":"Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.","volume":"169","author":"Rakovitch","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"crv240013r70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-021-06187-7","article-title":"DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low\/intermediate-risk DCIS.","volume":"188","author":"Rakovitch","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"crv240013r71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2022.06.072","article-title":"A novel biosignature identifies patients with DCIS with high risk of local recurrence after breast conserving surgery and radiation therapy.","volume":"115","author":"Vicini","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"crv240013r72","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"crv240013r73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamaoncol.2018.6269","article-title":"Association of magnetic resonance imaging and a 12-gene expression assay with breast ductal carcinoma in situ treatment.","volume":"5","author":"Lehman","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv240013r74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijrobp.2022.07.2311","article-title":"The elusive prize of radiation therapy predictive assays in breast cancer.","volume":"115","author":"Woodward","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"crv240013r75","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1200\/JCO.2016.67.8532","article-title":"Cost effectiveness of the oncotype DX DCIS score for guiding treatment of patients with ductal carcinoma in situ.","volume":"34","author":"Raldow","year":"2016","journal-title":"J Clin Oncol"},{"key":"crv240013r10","unstructured":"European Medicines Agency. Biomarker. Accessed July 7, 2024. https:\/\/www.ema.europa.eu\/en\/glossary\/biomarker#:~:text=An%20objective%20and%20quantifiable%20measure,an%20individual%20feels%20or%20function"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2829034\/jamaoncology_meattini_2025_rv_240013_1741392581.36436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:19:19Z","timestamp":1742491159000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2829034"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5780","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}